Get started
Work

502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer

Year: 2022
Type: article
DOI: 10.1016/j.annonc.2022.07.630
Authors: Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C-Y. Hsu, M.A. Bilen, O. Eton, L. Fecher, C. Hwang, H. Khan, R.R. McKay, E. Ruiz, L. Weissmann, M.A. Thompson, D. Shah, J. Warner, Y. Shyr, T.K. Choueiri, T. Wise-Draper
Institutions: Dana-Farber Cancer Institute, University of Cincinnati, University of Cincinnati Medical Center, Vanderbilt University Medical Center, Winship Cancer Institute, Hartford Hospital, University of Michigan, Michigan Medicine, Henry Ford Health, Henry Ford Hospital, Brown University, University of California San Diego, Instituto Nacional de Cancerología, Mount Auburn Hospital, Harvard University, Tempus Labs (United States), The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4295818064
FWCI:
Cites:
Cited by:
Related to: 10